The inhibitory effect was most potent in the xenografts harboring IDH2-shRNA and treated with cisplatin (blue curve), suggesting that targeting IDH2 could sensitize lung cancer cells to cisplatin in vivo. This evidence concerns the gene IDH2 and lung carcinoma.